Abstract
Venous thromboembolism (VTE) is a common complication in cancer patients. Prevention and treatment of VTE are major issues in cancer patients. For prophylaxis in the surgical setting, once-daily subcutaneous injections of low molecular weight heparin (LMWHs) are as effective and safe as multiple doses of unfractionated heparin (UFH). Extending prophylaxis with LMWH beyond hospital discharge reduces the risk of postoperative thrombosis after abdominal surgery for cancer. The clinical benefit from antithrombotic prophylaxis in medical cancer patients remains uncertain. For the initial treatment of VTE, LMWHs are effective and safe. For the long-term treatment of VTE, LMWHs have been shown to be more effective than the vitamin K antagonists in preventing recurrent VTE in cancer patients. The preliminary observations that LMWHs are associated with reduction in cancer mortality deserve further interest.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
